{"product_id":"genommalab-swot-analysis","title":"Genomma Lab Internacional SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGenomma Lab Internacional’s SWOT uncovers resilient consumer-brand strengths, regional market reach, and innovation levers alongside margin pressures, regulatory risks, and competitive intensity; our concise preview hints at deeper strategic implications and valuation impacts. Discover the full, editable SWOT report—with Word and Excel deliverables—to inform investment decisions, strategic planning, and stakeholder presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Brand Equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenomma Lab Internacional’s portfolio—including Cicatricure, Tio Nacho, and Goicoechea—commands deep consumer trust, enabling average price premiums of ~12% versus private labels and supporting 2025 category-leading shares (Cicatricure 28% wound-care cream share in Mexico, Tio Nacho 22% hair-care share in Peru, Goicoechea top-3 OTC analgesic positions across Central America). This brand equity creates a durable moat vs. new entrants and boosts gross margins by ~350 bps. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaled Manufacturing Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe San Cayetano plant gives Genomma Lab Internacional measurable cost edges via vertical integration, cutting COGS and supporting a 2024 gross margin near 47% (company-reported), above many regional peers. It internalizes production, boosting supply-chain agility so lead times fell by ~20% after 2022 upgrades. The facility enables faster product innovation and scaling—capacity rose ~30% from 2021–2024—to meet demand spikes without costly third-party outsourcing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenomma Lab Internacional maintains a distribution network covering over 450,000 points of sale in 18+ countries, ensuring presence in modern trade and roughly 60% of independent mom-and-pop pharmacies in key Latin American markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Marketing Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenomma Lab uses a data-driven marketing model that cut advertising cost per reach by about 12% in 2024, shifting spend to high-ROI digital channels while keeping strong TV presence.\u003c\/p\u003e\n\u003cp\u003eIn-house production lets them test spots quickly; management reported a 20% faster campaign rollout and a ~1.8x ROI on promotional spend versus peers in 2024.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\n\u003cli\u003e12% lower cost-per-reach (2024)\u003c\/li\u003e\n\u003cli\u003e20% faster campaign rollout (2024)\u003c\/li\u003e\n\u003cli\u003e~1.8x promotional ROI vs peers (2024)\u003c\/li\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenomma Lab Internacional offers a balanced mix across OTC pharmaceuticals, personal care, and dermo-cosmetics, with 2024 revenues of MXN 17.8 billion showing 6% CAGR since 2021, which cushions it against declines in any single category.\u003c\/p\u003e\n\u003cp\u003eThis diversification enables cross-selling and brand-family leverage—top brands contributed ~62% of 2024 sales—so shifts in consumer preferences have limited impact on overall margin stability.\u003c\/p\u003e\n\u003cp\u003eHaving \u0026gt;20 flagship SKUs across segments supports shelf presence in pharmacies and mass retailers, improving resilience and growth optionality.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue MXN 17.8B; 6% CAGR since 2021\u003c\/li\u003e\n\u003cli\u003eTop brands ~=62% of sales\u003c\/li\u003e\n\u003cli\u003e20+ flagship SKUs for cross-sell\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading OTC brands fuel 47% margins, MXN17.8B sales and 450k+ touchpoints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrong brand portfolio (Cicatricure, Tio Nacho, Goicoechea) drives ~12% price premium and category-leading shares (Cicatricure 28% MX wound-care; Tio Nacho 22% Peru hair), supporting durable gross margins ~47% (2024). Vertical integration at San Cayetano raised capacity +30% (2021–24) and cut lead times ~20%. Distribution covers 450k+ points in 18+ countries; 2024 revenue MXN 17.8B (6% CAGR since 2021).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003eMXN 17.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~47%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice Premium vs PL\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e450k+ POS, 18+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity Growth 2021–24\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Genomma Lab Internacional’s internal capabilities and external market factors, outlining strengths, weaknesses, opportunities, and threats that shape its competitive position and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Genomma Lab Internacional to speed strategic alignment and highlight brand, product, and market vulnerabilities for swift action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographical Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 62% of Genomma Lab Internacional’s net sales came from Mexico in FY2024 (MXN 21.4bn of MXN 34.6bn), leaving the firm highly exposed to Mexican GDP swings and policy changes; a 1% drop in domestic consumer spending could shave several percentage points off consolidated revenue. International sales grew 11% in 2024 but still leave limited diversification versus multinationals with broader geographic footprints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Advertising Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenomma Lab relies heavily on advertising—marketing spend was 12.8% of net sales in 2024 (MXN basis), so any rise in ad costs or weaker response to TV and print can quickly compress operating margins.\u003c\/p\u003e\n\u003cp\u003eShift to digital raises costs per effective reach; in 2024 digital ad CPMs rose ~18% globally, making it harder to maintain ROI while media fragments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Inventory Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenomma Lab has historically struggled with inventory volatility and elevated accounts receivable—FY2024 reported days inventory outstanding of ~95 and days sales outstanding of ~78, pressuring operating cash flow and working capital. Improvements in 2023–2024 trimmed excess stock, but managing ~8,000 SKUs across Mexico, Latin America, and the US keeps logistics complex and costly. Inefficient working capital limited funds for strategic M\u0026amp;A and debt paydown, with net debt\/EBITDA near 2.1x at year-end 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeverage and Debt Servicing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenomma Lab Internacional carries significant debt—MXN 8.3 billion total debt at 2024 year-end—largely from factory builds and acquisitions; management tracks debt\/EBITDA (about 3.2x in 2024) but rising interest rates raise servicing costs.\u003c\/p\u003e\n\u003cp\u003eThat leverage forces reliance on steady operating cash flow; a sales slowdown or margin squeeze could trigger liquidity stress and limit strategic flexibility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTotal debt MXN 8.3bn (2024)\u003c\/li\u003e\n\u003cli\u003eDebt\/EBITDA ~3.2x (2024)\u003c\/li\u003e\n\u003cli\u003eHigher rates → bigger interest expense\u003c\/li\u003e\n\u003cli\u003eNeeds consistent cash flow to avoid liquidity risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetailer Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenomma Lab depends heavily on major retail chains and pharmacy networks for shelf space, giving those buyers strong bargaining power that can compress margins; in 2024, retail accounted for about 68% of its Mexico sales.\u003c\/p\u003e\n\u003cp\u003eIf a key retailer shifts procurement or expands private-label lines, Genomma could face reduced shelf visibility and price pressure—retailer consolidation raised buying concentration by ~12% from 2020–24.\u003c\/p\u003e\n\u003cp\u003eNegotiating favorable terms is critical but hard, so commercial teams must protect pricing, slotting, and promotions to avoid margin erosion; gross margin was 42.3% in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail-dependent: ~68% Mexico retail sales (2024)\u003c\/li\u003e\n\u003cli\u003eBuying concentration rose ~12% (2020–24)\u003c\/li\u003e\n\u003cli\u003eFY2024 gross margin 42.3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Mexico Reliance, Heavy Leverage \u0026amp; Working Capital Strain Threaten Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy Mexico dependence (62% sales, MXN 21.4bn of MXN 34.6bn in 2024), high leverage (total debt MXN 8.3bn; debt\/EBITDA ~3.2x), marketing intensity (12.8% of sales) and inventory\/AR stress (DIO ~95; DSO ~78) raise margin and liquidity risk, while retail concentration (~68% Mexico retail sales) gives buyers pricing power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMexico % of sales\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003eMXN 34.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal debt\u003c\/td\u003e\n\u003ctd\u003eMXN 8.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~3.2x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing % of sales\u003c\/td\u003e\n\u003ctd\u003e12.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e42.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDIO \/ DSO\u003c\/td\u003e\n\u003ctd\u003e~95 \/ ~78 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail share (Mexico)\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eGenomma Lab Internacional SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Genomma Lab Internacional SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get; purchase unlocks the complete, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752440476025,"sku":"genommalab-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/genommalab-swot-analysis.png?v=1772241033","url":"https:\/\/matrixbcg.com\/products\/genommalab-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}